{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:47:22Z","timestamp":1784544442279,"version":"3.55.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiologic Clinics of North America"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.rcl.2021.05.011","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T01:32:02Z","timestamp":1628818322000},"page":"813-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["PET Imaging for Gynecologic Malignancies"],"prefix":"10.1016","volume":"59","author":[{"given":"Saul N.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Itani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrokh","family":"Dehdashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcl.2021.05.011_bib1","volume":"vol. 11","year":"2019"},{"issue":"11","key":"10.1016\/j.rcl.2021.05.011_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00066-011-4002-z","article-title":"Imaging of female pelvic malignancies regarding MRI, CT, and PET\/CT: Part 2","volume":"187","author":"Alt","year":"2011","journal-title":"Strahlenther Onkol"},{"issue":"10","key":"10.1016\/j.rcl.2021.05.011_bib3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00066-011-4001-0","article-title":"Imaging of female pelvic malignancies regarding MRI, CT, and PET\/CT : part 1","volume":"187","author":"Brocker","year":"2011","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2214\/ajr.146.6.1115","article-title":"MRI of the female pelvis: a review","volume":"146","author":"Hricak","year":"1986","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40644-015-0037-1","article-title":"Diffusion-weighted imaging and dynamic contrast-enhanced MRI in assessing response and recurrent disease in gynaecological malignancies","volume":"15","author":"Hameeduddin","year":"2015","journal-title":"Cancer Imaging"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2214\/AJR.14.12567","article-title":"The clinical impact of gynecologic MRI","volume":"204","author":"Ratner","year":"2015","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"10.1016\/j.rcl.2021.05.011_bib7","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00259-011-1842-9","article-title":"Value of a Dixon-based MR\/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions","volume":"38","author":"Eiber","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10334-012-0345-4","article-title":"Image artifacts from MR-based attenuation correction in clinical, whole-body PET\/MRI","volume":"26","author":"Keller","year":"2013","journal-title":"Magma"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1677\/joe.0.1630379","article-title":"Estrogen receptor beta\u2013a new dimension in estrogen mechanism of action","volume":"163","author":"Gustafsson","year":"1999","journal-title":"J\u00a0Endocrinol"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2967\/jnumed.114.147579","article-title":"Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16\u03b1-18F-fluoro-17\u03b2-estradiol PET\/CT","volume":"56","author":"van Kruchten","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.rcl.2021.05.011_bib11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2967\/jnumed.116.180158","article-title":"Synthesis and Evaluation of the Estrogen Receptor \u03b2-Selective Radioligand 2-18F-Fluoro-6-(6-Hydroxynaphthalen-2-yl)Pyridin-3-ol: Comparison with 16\u03b1-18F-Fluoro-17\u03b2-Estradiol","volume":"58","author":"Antunes","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib12","doi-asserted-by":"crossref","first-page":"e58938","DOI":"10.1371\/journal.pone.0058938","article-title":"Limits of [18F]-FLT PET as a biomarker of proliferation in oncology","volume":"8","author":"McKinley","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.rcl.2021.05.011_bib13","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1007\/s00259-002-0925-z","article-title":"Early changes in [18F]FLT uptake after chemotherapy: an experimental study","volume":"29","author":"Dittmann","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.rcl.2021.05.011_bib14","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2967\/jnumed.110.076794","article-title":"Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells","volume":"51","author":"Plotnik","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11307-006-0039-2","article-title":"Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology","volume":"8","author":"Shields","year":"2006","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"10.1016\/j.rcl.2021.05.011_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1120\/jacmp.v15i4.4780","article-title":"Spatial mapping of functional pelvic bone marrow using FLT PET","volume":"15","author":"McGuire","year":"2014","journal-title":"J\u00a0Appl Clin Med Phys"},{"key":"10.1016\/j.rcl.2021.05.011_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2385-7-3","article-title":"Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses","volume":"7","author":"Turcotte","year":"2007","journal-title":"BMC Nucl Med"},{"issue":"4","key":"10.1016\/j.rcl.2021.05.011_bib18","first-page":"365","article-title":"PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence","volume":"4","author":"Lopci","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.semnuclmed.2007.07.001","article-title":"Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole","volume":"37","author":"Lee","year":"2007","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0360-3016(92)91001-4","article-title":"Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole","volume":"22","author":"Koh","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.rcl.2021.05.011_bib21","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0360-3016(02)04477-2","article-title":"Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report","volume":"55","author":"Dehdashti","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.107.048520","article-title":"Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone)","volume":"49","author":"Dehdashti","year":"2008","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.rcl.2021.05.011_bib23","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2967\/jnumed.108.051326","article-title":"An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix","volume":"49","author":"Lewis","year":"2008","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.rcl.2021.05.011_bib24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.rcl.2013.05.006","article-title":"PET\/CT in gynecologic malignancies","volume":"51","author":"Brunetti","year":"2013","journal-title":"Radiol Clin North Am"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2011.10.009","article-title":"The epidemiology of endometrial and ovarian cancer","volume":"26","author":"Cramer","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib27","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1148\/rg.326125519","article-title":"The revised FIGO staging system for uterine malignancies: implications for MR imaging","volume":"32","author":"Freeman","year":"2012","journal-title":"Radiographics"},{"key":"10.1016\/j.rcl.2021.05.011_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40644-016-0069-1","article-title":"MRI of endometrium cancer - how we do it","volume":"16","author":"Meissnitzer","year":"2016","journal-title":"Cancer Imaging"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib29","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1148\/rg.2015140086","article-title":"Pathways of lymphatic spread in gynecologic malignancies","volume":"35","author":"Pa\u00f1o","year":"2015","journal-title":"Radiographics"},{"issue":"11","key":"10.1016\/j.rcl.2021.05.011_bib30","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1016\/j.ejrad.2012.01.024","article-title":"18F-FDG PET or PET\/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis","volume":"81","author":"Chang","year":"2012","journal-title":"Eur J Radiol"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib31","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2967\/jnumed.115.170597","article-title":"High Diagnostic Value of 18F-FDG PET\/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature","volume":"57","author":"Bollineni","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.rcl.2021.05.011_bib32","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s00259-011-2057-9","article-title":"Prognostic significance of SUVmax (maximum standardized uptake value) measured by [1\u2078F]FDG PET\/CT in endometrial cancer","volume":"39","author":"Kitajima","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.rcl.2021.05.011_bib33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3346\/jkms.2010.25.7.1029","article-title":"Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease","volume":"25","author":"Ryu","year":"2010","journal-title":"J\u00a0Korean Med Sci"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MNM.0b013e32834e41a6","article-title":"Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging","volume":"33","author":"Sharma","year":"2012","journal-title":"Nucl Med Commun"},{"issue":"8","key":"10.1016\/j.rcl.2021.05.011_bib35","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2967\/jnumed.119.233940","article-title":"PET\/MRI Versus PET\/CT for Whole-Body Staging: Results from a Single-Center Observational Study on 1,003 Sequential Examinations","volume":"61","author":"Martin","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00259-019-04452-y","article-title":"PET\/MRI versus PET\/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations","volume":"47","author":"Mayerhoefer","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.rcl.2021.05.011_bib37","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1007\/s00259-019-04402-8","article-title":"Hybrid PET\/MRI in major cancers: a scoping review","volume":"46","author":"Morsing","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40644-020-00357-4","article-title":"Diagnostic value of 18F-FDG PET\/MRI for staging in patients with endometrial cancer","volume":"20","author":"Tsuyoshi","year":"2020","journal-title":"Cancer Imaging"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.crad.2019.10.018","article-title":"FDG-PET\/MRI with high-resolution DWI characterises the distinct phenotypes of endometrial cancer","volume":"75","author":"Tsuyoshi","year":"2020","journal-title":"Clin Radiol"},{"key":"10.1016\/j.rcl.2021.05.011_bib40","doi-asserted-by":"crossref","first-page":"e7081","DOI":"10.7717\/peerj.7081","article-title":"Comparison of integrated PET\/MRI with PET\/CT in evaluation of endometrial cancer: a retrospective analysis of 81 cases","volume":"7","author":"Bian","year":"2019","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2463\/mrms.mp.2016-0128","article-title":"Evaluating Myometrial Invasion in Endometrial Cancer: Comparison of Reduced Field-of-view Diffusion-weighted Imaging and Dynamic Contrast-enhanced MR Imaging","volume":"17","author":"Takeuchi","year":"2018","journal-title":"Magn Reson Med Sci"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"106","author":"Singh","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.rcl.2021.05.011_bib44","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2967\/jnumed.108.060145","article-title":"Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET","volume":"50","author":"Tsujikawa","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1148\/radiol.2482071379","article-title":"Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET\u2013initial experience","volume":"248","author":"Tsujikawa","year":"2008","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.rcl.2021.05.011_bib46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2967\/jnumed.112.113472","article-title":"18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis","volume":"54","author":"Zhao","year":"2013","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib47","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12149-012-0597-0","article-title":"18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma","volume":"26","author":"Yamane","year":"2012","journal-title":"Ann Nucl Med"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5528\/wjtm.v3.i1.1","article-title":"Epithelial ovarian cancer: An overview","volume":"3","author":"Desai","year":"2014","journal-title":"World J Transl Med"},{"issue":"5","key":"10.1016\/j.rcl.2021.05.011_bib49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajog.2013.04.019","article-title":"The role of the fallopian tube in the origin of ovarian cancer","volume":"209","author":"Erickson","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3346\/jkms.2009.24.1.114","article-title":"Clinical characteristics of metastatic tumors to the ovaries","volume":"24","author":"Lee","year":"2009","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.rcl.2021.05.011_bib51","series-title":"Clinical gynecologic oncology","first-page":"313","article-title":"Epithelial Ovarian Cancer","author":"Copeland","year":"2007"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib53","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1148\/radiol.2233001850","article-title":"Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings","volume":"223","author":"Fenchel","year":"2002","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib54","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s10147-016-1013-x","article-title":"Analysis of positron emission tomography\/computed tomography in patients to differentiate between malignant transformation of endometrioma and endometrioma","volume":"21","author":"Kusunoki","year":"2016","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"10.1016\/j.rcl.2021.05.011_bib55","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11604-018-0755-y","article-title":"18F-FDG PET\/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value","volume":"36","author":"Liu","year":"2018","journal-title":"Jpn J Radiol"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2010.11.019","article-title":"Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction","volume":"121","author":"Semaan","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/0284186X.2010.500296","article-title":"Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer","volume":"50","author":"Risum","year":"2011","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib58","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.ejrad.2010.07.013","article-title":"FDG-PET\/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy","volume":"80","author":"De Iaco","year":"2011","journal-title":"Eur J Radiol"},{"issue":"8","key":"10.1016\/j.rcl.2021.05.011_bib59","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/MNM.0b013e3281afa256","article-title":"Diagnostic accuracy of 18F-FDG PET\/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology","volume":"28","author":"Castellucci","year":"2007","journal-title":"Nucl Med Commun"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2009.10.059","article-title":"Diagnosis and staging of primary ovarian cancer: correlation between PET\/CT, Doppler US, and CT or MRI","volume":"116","author":"Nam","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib61","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.3802\/jgo.2018.29.e98","article-title":"Performance of pre-treatment 1\u2078F-fluorodeoxyglucose positron emission tomography\/computed tomography for detecting metastasis in ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Han","year":"2018","journal-title":"J\u00a0Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11307-010-0468-9","article-title":"Value of FDG PET\/CT in patients with treated ovarian cancer and raised CA125 serum levels","volume":"14","author":"Palomar","year":"2012","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib63","first-page":"175","article-title":"Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography","volume":"26","author":"Peng","year":"2011","journal-title":"Cancer Biother Radiopharm"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib64","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/IGC.0b013e3181e82a7f","article-title":"Clinical utility of positron emission tomography\/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels","volume":"20","author":"Bhosale","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.rcl.2021.05.011_bib65","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s11547-011-0720-7","article-title":"MR-PET fusion imaging in evaluating adnexal lesions: a preliminary study","volume":"116","author":"Fiaschetti","year":"2011","journal-title":"Radiol Med"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11604-009-0387-3","article-title":"Diagnostic performance of fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging fusion images of gynecological malignant tumors: comparison with positron emission tomography\/computed tomography","volume":"28","author":"Nakajo","year":"2010","journal-title":"Jpn J Radiol"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib67","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/sj.bjc.6602752","article-title":"Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer","volume":"93","author":"Hasan","year":"2005","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.rcl.2021.05.011_bib68","first-page":"2233","article-title":"CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup","volume":"8","author":"Bowman","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000077436","article-title":"Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study","volume":"66","author":"Papadimitriou","year":"2004","journal-title":"Oncology"},{"issue":"Suppl 1","key":"10.1016\/j.rcl.2021.05.011_bib70","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1186\/1472-6874-4-S1-S13","article-title":"Cancer of the Uterine Cervix","volume":"4","author":"Duarte-Franco","year":"2004","journal-title":"BMC Womens Health"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib71","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijgo.12749","article-title":"Revised FIGO staging for carcinoma of the cervix uteri","volume":"145","author":"Bhatla","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib72","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0090-8258(03)00402-5","article-title":"Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix","volume":"90","author":"Tran","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib73","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1349-7006.2010.01532.x","article-title":"Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography\/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis","volume":"101","author":"Choi","year":"2010","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib74","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/cncr.26317","article-title":"Can radicality of surgery be safely modulated on the basis of MRI and PET\/CT imaging in locally advanced cervical cancer patients administered preoperative treatment?","volume":"118","author":"Ferrandina","year":"2012","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.rcl.2021.05.011_bib75","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2001.19.17.3745","article-title":"Lymph node staging by positron emission tomography in patients with carcinoma of the cervix","volume":"19","author":"Grigsby","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.rcl.2021.05.011_bib76","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2009.25.4151","article-title":"Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis","volume":"28","author":"Kidd","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib77","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/cncr.24972","article-title":"Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer","volume":"116","author":"Kidd","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib78","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00432-011-1092-z","article-title":"The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer","volume":"138","author":"Pan","year":"2012","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib79","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cpet.2017.11.004","article-title":"[18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer","volume":"13","author":"Viswanathan","year":"2018","journal-title":"PET Clin"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib80","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ygyno.2006.02.016","article-title":"Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis","volume":"103","author":"Chung","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib81","first-page":"227","article-title":"F18-FDG-PET\/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma","volume":"63","author":"Cetina","year":"2011","journal-title":"Rev Invest Clin"},{"issue":"4","key":"10.1016\/j.rcl.2021.05.011_bib82","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0360-3016(02)04287-6","article-title":"Posttherapy surveillance monitoring of cervical cancer by FDG-PET","volume":"55","author":"Grigsby","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.rcl.2021.05.011_bib83","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1002\/cncr.25991","article-title":"Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer","volume":"117","author":"Siva","year":"2011","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.rcl.2021.05.011_bib84","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1007\/s00261-018-1665-2","article-title":"Feasibility and diagnostic performance of hybrid PET\/MRI compared with PET\/CT for gynecological malignancies: a prospective pilot study","volume":"43","author":"Schwartz","year":"2018","journal-title":"Abdom Radiol (Ny)"},{"issue":"12","key":"10.1016\/j.rcl.2021.05.011_bib85","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s00259-015-3131-5","article-title":"Integrated PET\/MRI for whole-body staging of patients with primary cervical cancer: preliminary results","volume":"42","author":"Grueneisen","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib86","first-page":"1815","article-title":"Cervical cancer evaluated with integrated 18F-FDG PET\/MR","volume":"18","author":"Gong","year":"2019","journal-title":"Oncol Lett"},{"issue":"17","key":"10.1016\/j.rcl.2021.05.011_bib87","doi-asserted-by":"crossref","first-page":"28285","DOI":"10.18632\/oncotarget.16043","article-title":"Parameters of simultaneous 18F-FDG-PET\/MRI predict tumor stage and several histopathological features in uterine cervical cancer","volume":"8","author":"Surov","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib88","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jmri.27311","article-title":"PET\/MRI in Cervical Cancer: Associations Between Imaging Biomarkers and Tumor Stage, Disease Progression, and Overall Survival","volume":"53","author":"Shih","year":"2021","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib89","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/gyno.2000.6109","article-title":"Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer","volume":"81","author":"Abu-Rustum","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib90","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijrobp.2007.05.028","article-title":"Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment","volume":"70","author":"Torres","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib91","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.radonc.2015.11.018","article-title":"[(18)F]Fluoro-2-deoxy-2-d-glucose versus 3'-deoxy-3'-[(18)F]fluorothymidine for defining hematopoietically active pelvic bone marrow in gynecologic patients","volume":"118","author":"Wyss","year":"2016","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.rcl.2021.05.011_bib92","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s11307-007-0095-2","article-title":"Comparison of molecular markers of hypoxia and\u00a0imaging with (60)Cu-ATSM in cancer of the\u00a0uterine cervix","volume":"9","author":"Grigsby","year":"2007","journal-title":"Mol Imaging Biol"},{"issue":"Suppl 2","key":"10.1016\/j.rcl.2021.05.011_bib93","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijgo.12610","article-title":"Cancer of the vagina","volume":"143","author":"Adams","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib94","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijrobp.2004.12.011","article-title":"FDG-PET evaluation of vaginal carcinoma","volume":"62","author":"Lamoreaux","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib95","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2016.01.011","article-title":"The impact of FDG-PET\/CT in the management of patients with vulvar and vaginal cancer","volume":"140","author":"Robertson","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib96","doi-asserted-by":"crossref","first-page":"92","DOI":"10.6004\/jnccn.2017.0008","article-title":"Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Koh","year":"2017","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"2","key":"10.1016\/j.rcl.2021.05.011_bib97","first-page":"87","article-title":"[Utility of the PET\/CT in vulvar cancer management]","volume":"33","author":"Peir\u00f3","year":"2014","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib98","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/gyno.2002.6605","article-title":"Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer","volume":"85","author":"Cohn","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib99","first-page":"230","article-title":"Whole-body [18F]fluoro-2-deoxyglucose positron emission tomography scan as combined PET-CT staging prior to planned radical vulvectomy and inguinofemoral lymphadenectomy for squamous vulvar cancer: a correlation with groin node metastasis","volume":"35","author":"Kamran","year":"2014","journal-title":"Eur J Gynaecol Oncol"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib100","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2214\/AJR.12.9714","article-title":"Multimodality imaging of vulvar cancer: staging, therapeutic response, and complications","volume":"200","author":"Viswanathan","year":"2013","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.rcl.2021.05.011_bib101","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00330-014-3530-1","article-title":"Computed tomography, magnetic resonance imaging and FDG positron emission tomography in the management of vulvar malignancies","volume":"25","author":"Lin","year":"2015","journal-title":"Eur Radiol"},{"issue":"7","key":"10.1016\/j.rcl.2021.05.011_bib102","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00259-006-0317-x","article-title":"Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?","volume":"34","author":"Antunes","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.rcl.2021.05.011_bib103","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","article-title":"Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE","volume":"37","author":"Virgolini","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.rcl.2021.05.011_bib104","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0090-8258(91)90225-T","article-title":"Small cell carcinoma of the cervix: a clinical and flow-cytometric study","volume":"42","author":"Miller","year":"1991","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.rcl.2021.05.011_bib105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/RLU.0000000000001498","article-title":"Early Detection of Bone Metastasis in Small Cell Neuroendocrine Carcinoma of the Cervix by 68Ga-DOTATATE PET\/CT Imaging","volume":"42","author":"Damian","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.rcl.2021.05.011_bib106","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2967\/jnumed.119.236091","article-title":"64Cu-DOTATATE PET\/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial","volume":"61","author":"Delpassand","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"Suppl 1","key":"10.1016\/j.rcl.2021.05.011_bib107","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/annonc\/12.suppl_1.S9","article-title":"The role of overexpressed HER2 in transformation","volume":"12","author":"Neve","year":"2001","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.rcl.2021.05.011_bib108","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1158\/1078-0432.CCR-17-0311","article-title":"89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors","volume":"23","author":"Bensch","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rcl.2021.05.011_bib109","first-page":"1585","article-title":"PARP Inhibitors in Cancer Diagnosis and Therapy","volume":"10","author":"Chan","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.rcl.2021.05.011_bib110","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1172\/JCI97992","article-title":"A\u00a0PET imaging agent for evaluating PARP-1 expression in ovarian cancer","volume":"128","author":"Makvandi","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.rcl.2021.05.011_bib111","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.nucmedbio.2010.12.003","article-title":"Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3'deoxy-3-fluorothymidine positron emission tomography\/computed tomography imaging","volume":"38","author":"Richard","year":"2011","journal-title":"Nucl Med Biol"},{"issue":"7","key":"10.1016\/j.rcl.2021.05.011_bib112","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/RLU.0b013e318292ee9c","article-title":"18F-fluorothymidine PET is a potential predictive imaging biomarker of the response to gemcitabine-based chemotherapeutic treatment for recurrent ovarian cancer: preliminary results in three patients","volume":"38","author":"Tsuyoshi","year":"2013","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1016\/j.rcl.2021.05.011_bib113","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2967\/jnumed.109.073288","article-title":"18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model","volume":"51","author":"Aide","year":"2010","journal-title":"J\u00a0Nucl Med"}],"container-title":["Radiologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033838921000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033838921000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:52:58Z","timestamp":1758502378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033838921000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":113,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0033838921000725"],"URL":"https:\/\/doi.org\/10.1016\/j.rcl.2021.05.011","relation":{},"ISSN":["0033-8389"],"issn-type":[{"value":"0033-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET Imaging for Gynecologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Radiologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcl.2021.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}